Episode-based payment for cancer care: a proposed pilot for Medicare.

The steady introduction of more and more expensive cancer treatments has prompted policy makers to explore alternative payment approaches that might rein in costs. We propose a framework for "episode-based" payment during chemotherapy treatment, which would cover the costs of drugs and their administration for a predefined period of treatment and would have the potential to reduce costs and improve patient outcomes. Using the example of metastatic lung cancer treatment, we describe an approach that Medicare could pursue in order to test our proposal as a pilot program. If successful, the concept could be expanded to encompass longer time periods, other cancer diagnoses, and additional care components.

[1]  P. Bach,et al.  Pem and the cost of multicycle maintenance. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  C. Earle,et al.  How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment. , 2010, Health affairs.

[3]  M. Socinski,et al.  Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  W. Wong,et al.  Year one evaluation of regional pay for quality (P4Q) oncology program. , 2010 .

[5]  P. Bach Limits on Medicare's ability to control rising spending on cancer drugs. , 2009, The New England journal of medicine.

[6]  S. Altman,et al.  Payment reform options: episode payment is a good place to start. , 2009, Health affairs.

[7]  R. Reischauer,et al.  Collective accountability for medical care--toward bundled Medicare payments. , 2008, The New England journal of medicine.

[8]  Elaine L. Towle,et al.  Key practice indicators in office-based oncology practices: 2007 report on 2006 data. , 2007, Journal of oncology practice.

[9]  J. Davila,et al.  Receipt of Recommended Therapy by Patients with Advanced Colorectal Cancer , 2006, The American Journal of Gastroenterology.

[10]  P. Bach Using practice guidelines to assess cancer care quality. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Colin B Begg,et al.  Adherence to surveillance among patients with superficial bladder cancer. , 2003, Journal of the National Cancer Institute.

[12]  G. Scagliotti,et al.  Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Begg,et al.  Age and adjuvant chemotherapy use after surgery for stage III colon cancer. , 2001, Journal of the National Cancer Institute.

[14]  Lonny Reisman,et al.  Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. , 2010, Journal of oncology practice.

[15]  Handra,et al.  COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON–SMALL-CELL LUNG CANCER , 2001 .